Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 11,700 shares, a growth of 39.3% from the October 31st total of 8,400 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 45,300 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Alphabet Inc. acquired a new position in shares of Barinthus Biotherapeutics in the 2nd quarter valued at $2,119,000. Catalina Capital Group LLC acquired a new position in Barinthus Biotherapeutics in the second quarter valued at about $25,000. Ipswich Investment Management Co. Inc. purchased a new position in Barinthus Biotherapeutics during the second quarter worth about $32,000. Finally, M&G Plc acquired a new stake in shares of Barinthus Biotherapeutics during the second quarter valued at about $7,276,000. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BRNS has been the topic of a number of recent research reports. Alliance Global Partners lowered their price target on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a report on Tuesday, November 19th.

Barinthus Biotherapeutics Trading Up 3.3 %

Shares of BRNS stock traded up $0.03 on Friday, hitting $0.99. 132,074 shares of the stock traded hands, compared to its average volume of 74,560. Barinthus Biotherapeutics has a twelve month low of $0.81 and a twelve month high of $4.16. The firm’s 50-day moving average price is $1.23 and its two-hundred day moving average price is $1.44.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same quarter last year, the firm earned ($0.37) EPS. As a group, equities analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.